GS-9674 + Placebo to match GS-9674
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH)
Conditions
Nonalcoholic Steatohepatitis (NASH)
Trial Timeline
Oct 26, 2016 → Jan 9, 2018
NCT ID
NCT02854605About GS-9674 + Placebo to match GS-9674
GS-9674 + Placebo to match GS-9674 is a phase 2 stage product being developed by Gilead Sciences for Nonalcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02854605. Target conditions include Nonalcoholic Steatohepatitis (NASH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02854605 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH)